The causal relationship between inflammation and aortic stenosis has been explored using Mendelian randomization to estimate the genetically proxied effects of tocilizumab, canakinumab, and colchicine, based on data from two large European genome-wide association studies comprising over 500 000 individuals each.83 This analysis found that genetically proxied IL-6 inhibition via tocilizumab was associated with a reduced risk of aortic stenosis, while canakinumab showed no significant association. Here, IL6 is linked to aortic stenosis.